This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC) that has a specific genetic change called the KRAS G12C mutation. The trial is testing a medication called Adagrasib, which is taken as a film-coated tablet. Adagrasib is also known by its code name, MRTX849. The purpose of the study is to evaluate how effective two different dosing regimens of Adagrasib are for patients who have already received certain treatments for their cancer.

Participants in the study will receive one of two dosing regimens of Adagrasib. One group will take 600 mg of Adagrasib twice a day without regard to food, while the other group will take 400 mg twice a day with food. The study will monitor how well the cancer responds to these treatments and will also look at the overall survival of the participants, which means the length of time they live after starting the treatment. Additionally, the study will assess how long the treatment keeps the cancer from getting worse and how long any positive response to the treatment lasts.

The trial will also focus on the safety of Adagrasib by observing any side effects that occur during the study. Participants will report any symptoms they experience while taking the medication. The study will continue until 2027, allowing researchers to gather comprehensive data on the effectiveness and safety of Adagrasib for treating NSCLC with the KRAS G12C mutation.